JP2023518044A5 - - Google Patents

Info

Publication number
JP2023518044A5
JP2023518044A5 JP2022555714A JP2022555714A JP2023518044A5 JP 2023518044 A5 JP2023518044 A5 JP 2023518044A5 JP 2022555714 A JP2022555714 A JP 2022555714A JP 2022555714 A JP2022555714 A JP 2022555714A JP 2023518044 A5 JP2023518044 A5 JP 2023518044A5
Authority
JP
Japan
Prior art keywords
alkyl
pharmaceutically acceptable
solvate
acceptable salt
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2022555714A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023518044A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/022397 external-priority patent/WO2021188450A1/en
Publication of JP2023518044A publication Critical patent/JP2023518044A/ja
Publication of JP2023518044A5 publication Critical patent/JP2023518044A5/ja
Priority to JP2025033957A priority Critical patent/JP7892820B2/ja
Ceased legal-status Critical Current

Links

JP2022555714A 2020-03-16 2021-03-15 Nlrp3モジュレーター Ceased JP2023518044A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025033957A JP7892820B2 (ja) 2020-03-16 2025-03-04 Nlrp3モジュレーター

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062990363P 2020-03-16 2020-03-16
US62/990,363 2020-03-16
PCT/US2021/022397 WO2021188450A1 (en) 2020-03-16 2021-03-15 Nlrp3 modulators

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025033957A Division JP7892820B2 (ja) 2020-03-16 2025-03-04 Nlrp3モジュレーター

Publications (2)

Publication Number Publication Date
JP2023518044A JP2023518044A (ja) 2023-04-27
JP2023518044A5 true JP2023518044A5 (cg-RX-API-DMAC7.html) 2024-03-18

Family

ID=77747550

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022555714A Ceased JP2023518044A (ja) 2020-03-16 2021-03-15 Nlrp3モジュレーター
JP2025033957A Active JP7892820B2 (ja) 2020-03-16 2025-03-04 Nlrp3モジュレーター

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025033957A Active JP7892820B2 (ja) 2020-03-16 2025-03-04 Nlrp3モジュレーター

Country Status (16)

Country Link
US (4) US11603375B2 (cg-RX-API-DMAC7.html)
EP (1) EP4121059A4 (cg-RX-API-DMAC7.html)
JP (2) JP2023518044A (cg-RX-API-DMAC7.html)
KR (1) KR20220154165A (cg-RX-API-DMAC7.html)
CN (1) CN115605209B (cg-RX-API-DMAC7.html)
AR (1) AR121573A1 (cg-RX-API-DMAC7.html)
AU (1) AU2021237477A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022018480A2 (cg-RX-API-DMAC7.html)
CA (1) CA3175729A1 (cg-RX-API-DMAC7.html)
CL (1) CL2022002531A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022014499A2 (cg-RX-API-DMAC7.html)
IL (1) IL296488A (cg-RX-API-DMAC7.html)
MX (1) MX2022011576A (cg-RX-API-DMAC7.html)
PH (1) PH12022552447A1 (cg-RX-API-DMAC7.html)
TW (1) TWI901652B (cg-RX-API-DMAC7.html)
WO (1) WO2021188450A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020312800B2 (en) 2019-07-17 2026-04-23 Zomagen Biosciences Ltd N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4,5,6,7-tetrahydrobenzofuran -2-sulfonamide derivatives and related compounds as NLPR3 modulators for the treatment of multiple sclerosis (ms)
WO2021009567A1 (en) 2019-07-17 2021-01-21 Zomagen Biosciences Ltd Nlrp3 modulators
CA3175729A1 (en) 2020-03-16 2021-09-23 Zomagen Biosciences Ltd Nlrp3 modulators
CN117279903A (zh) * 2021-02-10 2023-12-22 杭州英创医药科技有限公司 作为nlrp3抑制剂的化合物
CN117247393A (zh) * 2022-06-17 2023-12-19 成都百裕制药股份有限公司 酰胺衍生物及其制备方法和在医药上的应用
WO2025255532A1 (en) * 2024-06-07 2025-12-11 Zomagen Biosciences Ltd Combination therapies

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2119705A1 (en) * 2008-05-14 2009-11-18 AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.p.A. 3-Aminocarbozole compound, pharmaceutical composition containing it and preparation method therefor
ES2668834T3 (es) * 2008-09-08 2018-05-22 Merck Serono Sa Pirimidinas macrociclicas como inhibidores de proteína quinasas
CN107207431B (zh) * 2015-01-13 2021-02-09 维夫雷昂生物科学有限责任公司 Ca2+释放激活的Ca2+(CRAC)通道的调节剂及其药物用途
JP6929792B2 (ja) 2015-02-16 2021-09-01 ザ ユニバーシティ オブ クィーンズランド スルホニル尿素及び関連化合物並びにその使用
FR3046933B1 (fr) * 2016-01-25 2018-03-02 Galderma Research & Development Inhibiteurs nlrp3 pour le traitement des pathologies cutanees inflammatoires
BR112018016671A2 (pt) 2016-02-16 2018-12-26 The University Of Queensland sulfonilureias e compostos relacionados e uso do mesmo
MA44729A (fr) * 2016-04-18 2021-05-12 Novartis Ag Composés et compositions pour traiter des états associés à une activité de nlrp
US11447460B2 (en) 2016-04-18 2022-09-20 Novartis Ag Compounds and compositions for treating conditions associated with NLRP activity
UA126675C2 (uk) * 2017-01-23 2023-01-11 Дженентек, Інк. Хімічні сполуки як інгібітори активності інтерлейкіну-1
US11840543B2 (en) * 2017-05-24 2023-12-12 The University Of Queensland Compounds and uses
CN110914256A (zh) * 2017-07-07 2020-03-24 英夫拉索姆有限公司 新颖磺酰胺羧酰胺化合物
MX2020001776A (es) 2017-08-15 2020-03-24 Inflazome Ltd Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3.
AU2018317800A1 (en) * 2017-08-15 2020-02-13 Inflazome Limited Novel sulfonamide carboxamide compounds
TW201910317A (zh) 2017-08-15 2019-03-16 愛爾蘭商英弗雷佐姆有限公司 新穎化合物
ES2927851T3 (es) 2017-10-17 2022-11-11 Novartis Ag Sulfonamidas y composiciones de las mismas para tratar afecciones asociadas con la actividad de NLRP
GB201721185D0 (en) 2017-12-18 2018-01-31 Nodthera Ltd Sulphonyl urea derivatives
US20200399242A1 (en) * 2018-03-02 2020-12-24 Inflazome Limited Novel compounds
MA53172A (fr) * 2018-07-20 2021-05-26 Hoffmann La Roche Composés de sulfonimidamide en tant qu'inhibiteurs de l'activité de l'interleukine 1
US20230011652A1 (en) 2018-10-24 2023-01-12 Novartis Ag Compounds and compositions for treating conditions associated with nlrp activity
AU2020312800B2 (en) 2019-07-17 2026-04-23 Zomagen Biosciences Ltd N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4,5,6,7-tetrahydrobenzofuran -2-sulfonamide derivatives and related compounds as NLPR3 modulators for the treatment of multiple sclerosis (ms)
WO2021009567A1 (en) 2019-07-17 2021-01-21 Zomagen Biosciences Ltd Nlrp3 modulators
CA3175729A1 (en) 2020-03-16 2021-09-23 Zomagen Biosciences Ltd Nlrp3 modulators

Similar Documents

Publication Publication Date Title
JP2021523200A5 (cg-RX-API-DMAC7.html)
JP2022545633A5 (cg-RX-API-DMAC7.html)
JP2021522262A5 (cg-RX-API-DMAC7.html)
HRP20120202T1 (hr) AMIDOFENOKSIINDAZOLI, KORISNI KAO INHIBITORI c-MET
JP2019531279A5 (cg-RX-API-DMAC7.html)
JP2022529311A5 (cg-RX-API-DMAC7.html)
JP2007508359A5 (cg-RX-API-DMAC7.html)
JP2017525737A5 (cg-RX-API-DMAC7.html)
RU2015149767A (ru) Дейтерированные диаминопиримидиновые соединения и фармацевтические композиции, содержащие такие соединения
JP2011529054A5 (cg-RX-API-DMAC7.html)
JP2011527331A5 (cg-RX-API-DMAC7.html)
JP2005534635A5 (cg-RX-API-DMAC7.html)
JP2011037841A5 (cg-RX-API-DMAC7.html)
JP2010532387A5 (cg-RX-API-DMAC7.html)
JP2023520396A5 (cg-RX-API-DMAC7.html)
JP2005508349A5 (cg-RX-API-DMAC7.html)
JP2007508360A5 (cg-RX-API-DMAC7.html)
JP2007246474A5 (cg-RX-API-DMAC7.html)
JP2022510925A5 (cg-RX-API-DMAC7.html)
JP2022534704A5 (cg-RX-API-DMAC7.html)
RU2013138372A (ru) Производные азетидина, применяемые для лечения метаболических и воспалительных заболеваний
JP2023552610A5 (cg-RX-API-DMAC7.html)
JP2011509301A5 (cg-RX-API-DMAC7.html)
CA2702482A1 (en) Substituted n-phenyl-bipyrrolidine carboxamides and therapeutic use thereof
JP2006507355A5 (cg-RX-API-DMAC7.html)